RAPT Therapeutics
RAPT
RAPT was delisted on the 2nd of March, 2026.
85 hedge funds and large institutions have $616M invested in RAPT Therapeutics in 2022 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 30 increasing their positions, 30 reducing their positions, and 24 closing their positions.
84,000% more call options, than puts
Call options by funds: $1.68M | Put options by funds: $2K
0.07% more ownership
Funds ownership: 11.78% → 11.85% (+0.07%)
0% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 30
14% less funds holding
Funds holding: 99 → 85 (-14)
20% less funds holding in top 10
Funds holding in top 10: 10 → 8 (-2)
40% less capital invested
Capital invested by funds: $1.02B → $616M (-$403M)
58% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$22M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$17.7M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$8.46M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$3.72M |
| 5 |
O
OrbiMed
New York
|
+$3.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$25.2M |
| 2 |
ACM
Atika Capital Management
New York
|
-$7.72M |
| 3 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$4.22M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
-$4.15M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$4.02M |
RAPT Hedge Fund Activity: Q1 2022 in Review
85 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q1 2022, worth a combined $616M — down 40% from $1.02B a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of RAPT and 10 opened new positions — a net loss of 14 holders — while 30 trimmed existing stakes and 30 added.
The largest buyer was Fidelity Investments, adding an estimated $22M. The largest seller was Wellington Management Group, cutting an estimated $25.2M.
- 85 institutional investors held RAPT Therapeutics (RAPT) as of Q1 2022, down from 99 in Q4 2021.
- Funds reported $616M of RAPT Therapeutics stock for Q1 2022, down 40% quarter-over-quarter.
- 10 funds opened new RAPT Therapeutics positions in Q1 2022 and 24 closed out, a net change of -14 holders.
- The largest RAPT Therapeutics buyer in Q1 2022 was Fidelity Investments, an estimated $22M added.
- The largest RAPT Therapeutics seller in Q1 2022 was Wellington Management Group, an estimated $25.2M sold.
Based on aggregated 13F filings for Q1 2022.